Get Enquiry

Gastrointestinal Stromal Tumors

Application Details :

GISTs, or gastrointestinal stromal tumors, are a relatively rare but clinically relevant kind of cancer that primarily develops in the gastrointestinal system. These tumors arise from specialized cells known as interstitial cells of Cajal (ICCs), which play an important role in regulating gastrointestinal contractions. GISTs can develop in any portion of the gastrointestinal tract, including the stomach, small intestine, large intestine, esophagus, and even the abdominal cavity. The stomach (approximately 60%) and small intestine (about 30%) contain the majority of GISTs. GISTs are distinguished by their ability to behave in both benign and malignant ways. Some GISTs are non-cancerous (benign), whilst others can be aggressive and progress to malignancy (malignant). Several factors influence this behavior, including the tumor's size and location, as well as its biological features. GISTs are frequently classified based on their mitotic rate (the rate at which tumor cells develop) and cellular morphology under the microscope. The most common symptom of GISTs is abdominal pain or discomfort, which is caused by tumor growth and strain on adjacent organs. GI bleeding, nausea, vomiting, and accidental weight loss are all possible symptoms. However, it's important to note that some GISTs can be asymptomatic for a long time, making early detection and diagnosis difficult. GISTs are often diagnosed using a combination of medical imaging, including CT scans, MRI, and endoscopy, as well as a biopsy, to confirm the presence of a GIST and define its unique characteristics. Immunohistochemistry is the most important diagnostic tool for GISTs, as it distinguishes them from other forms of tumors. GISTs are often treated with surgical removal of the tumor, as well as targeted therapy with drugs such as imatinib (Gleevec). Imatinib has transformed the treatment of GISTs by specifically targeting the underlying genetic defects that fuel tumor growth. In the case of unresectable or metastatic GISTs, imatinib-based targeted therapy can be a life-extending and disease-controlling option. To summarize, Gastrointestinal Stromal Tumors are a rare but notable type of malignancies that develop in the GI system, frequently with varied degrees of aggressiveness. Individuals diagnosed with GISTs now have a better prognosis thanks to early discovery and effective treatment, which includes surgery and targeted therapy. However, due to the intricacy and variety of these tumors, a multidisciplinary approach comprising oncologists, surgeons, and pathologists is essential for delivering the best possible care for GIST patients.